Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • ankitgupta.iitg
    Junior Member
    • Oct 2009
    • 1

    Problems with de novo transcriptome assembly using 454 Titanium series

    Hi,

    I am trying to do a de novo transcriptome assembly for a non-model organism using 454 GS FLX Titanium series. I have 656878 reads with average length of 377 base pairs which after cleaning, masking and assembling using TGICL (uses CAP3 to assemble), I have 87282 contigs and 317205 singletons. My contigs have an average length of 700 bp and an average coverage depth of 1.9.

    I am afraid that the coverage is very low and am not getting enough contigs due to the large number of singletons. Any ideas on how can I improve my assembly? Are these problems inherent to the TGICL assembly program or should I use some other software like MIRA? Are there any other parameters that I should look at to give me a better idea about the quality of my contigs and assembly?

    Thanks
  • 454Sequencing
    Member
    • Apr 2009
    • 22

    #2
    Hi ankitgupta.iitg,

    If you've not heard previously, 454 Life Sciences will shortly launch a new transcriptome assembler as part of our next product update. I think you will find this new tool extremely useful in your de novo transcriptome assembly efforts. For more details please see the following:



    In the meantime, I'd recommend following up with your Roche representative. One of our bioinformatics Regional Applications Consultants should be able to lend a hand with your question.

    Best regards,
    Jason

    Technical Product Manager
    454 Life Sciences, A Roche Company
    Technical Product Manager
    454 Life Sciences, A Roche Company

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      07-09-2026, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      07-08-2026, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 07-24-2026, 12:17 PM
    0 responses
    21 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-23-2026, 11:41 AM
    0 responses
    19 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-20-2026, 11:10 AM
    0 responses
    26 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-13-2026, 10:26 AM
    0 responses
    38 views
    0 reactions
    Last Post SEQadmin2  
    Working...